28 29 Letrozole, a third-generation aromatase inhibitor, prevents the production of estrogens in 30 the final step in conversion from androgens. Due to its efficacy at suppressing estrogens, 31letrozole has recently taken favor as a first-line adjuvant treatment for hormone-responsive breast 32 cancer in middle-aged women. Though patient response to letrozole has generally been positive, 33there is conflicting evidence surrounding its effects on the development of depression. It is 34 possible that the potential adverse effects of letrozole on mood are a result of the impact of 35 hormonal fluctuations on neurogenesis in the hippocampus. Thus, to clarify the effects of 36 letrozole on the hippocampus and behavior, we examined how chronic administration affects 37 hippocampal neurogenesis and depressive-like behavior in middle-aged, intact female mice. 38Mice were given either letrozole (1mg/kg) or vehicle by injection (i.p.) daily for 3 weeks. 39Depressive-like behavior was assessed during the last 3 days of treatment using the forced swim 40test, tail suspension test, and sucrose preference test. The production of new neurons was 41 quantified using the immature neuronal marker doublecortin (DCX), and cell proliferation was 42 quantified using the endogenous marker Ki67. We found that letrozole increased DCX and Ki67 43 expression and maturation in the dentate gyrus, but had no significant effect on depressive-like 44behavior. Our findings suggest that a reduction in estrogens in middle-aged females increases 45 hippocampal neurogenesis without any adverse impact on depressive-like behavior; as such, this 46 furthers our understanding of how estrogens modulate neurogenesis, and to the rationale for the 47 utilization of letrozole in the clinical management of breast cancer. 48 49 50